Tricida Inc(TCDA) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Current Price

$4.06

RSI

21.732

Beta:

1.369798

February 26, 2021
15.1M
-103.6M

-307.336 %
-75.031 %
5.957 %
-26.099 %

$-18,373,000
$-5,744,000
$-3,137,000
-68.737 %
-45.386 %

$-264,791,000
$-176,905,000
$-125,208,000
-33.191 %
-29.223 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.